JD HEALTH
06618
BIDU-SW
09888
ALI HEALTH
00241
JD-SW
09618
NTES-S
09999
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -8.21%934.32M | 16.52%2.06B | 64.22%1.02B | 19.91%1.77B | 39.52%619.79M | 98.51%1.47B | -5.18%444.22M | 12.14%742.51M | 52.08%468.48M | 19.31%662.1M |
Operating income | -8.21%934.32M | 16.52%2.06B | 64.22%1.02B | 19.91%1.77B | 39.52%619.79M | 98.51%1.47B | -5.18%444.22M | 12.14%742.51M | 52.08%468.48M | 19.31%662.1M |
Cost of sales | -15.52%-441.41M | -31.54%-828.03M | -73.58%-382.12M | -10.71%-629.47M | -39.69%-220.14M | -50.44%-568.58M | 35.03%-157.59M | -12.10%-377.95M | -57.81%-242.54M | -9.51%-337.15M |
Operating expenses | -15.52%-441.41M | -31.54%-828.03M | -73.58%-382.12M | -10.71%-629.47M | -39.69%-220.14M | -50.44%-568.58M | 35.03%-157.59M | -12.10%-377.95M | -57.81%-242.54M | -9.51%-337.15M |
Gross profit | -22.46%492.9M | 8.21%1.23B | 59.07%635.71M | 25.69%1.14B | 39.43%399.65M | 148.35%905.38M | 26.87%286.63M | 12.19%364.56M | 46.38%225.93M | 31.52%324.95M |
Selling expenses | 43.70%-41.33M | 19.17%-166.74M | 10.77%-73.41M | -17.45%-206.28M | -69.81%-82.27M | -157.12%-175.63M | -19.88%-48.45M | 15.56%-68.31M | -15.09%-40.42M | -13.64%-80.89M |
Administrative expenses | 7.46%-56.16M | -17.82%-103.65M | -63.48%-60.69M | -35.76%-87.97M | -12.89%-37.12M | -109.77%-64.8M | -4.58%-32.89M | 28.51%-30.89M | -1.19%-31.44M | -21.32%-43.21M |
Research and development expenses | 8.95%-67.23M | -11.80%-140.5M | -47.73%-73.84M | -35.81%-125.67M | -32.67%-49.98M | -71.94%-92.53M | -41.49%-37.68M | -40.59%-53.82M | -70.43%-26.63M | -35.28%-38.28M |
Operating interest expense | ---- | 8.74%-637K | ---- | -9.58%-698K | -55.92%-329K | -27.66%-637K | 44.33%-211K | ---499K | ---379K | ---- |
Special items of operating profit | 15.33%41.76M | 48.06%67.52M | 49.78%36.21M | 58.10%45.6M | 76.02%24.18M | 10.08%28.84M | -6.08%13.74M | 69.12%26.2M | 104.27%14.62M | 62.46%15.49M |
Operating profit | -20.27%369.94M | 16.30%887.35M | 82.59%463.99M | 27.03%762.98M | 40.28%254.12M | 153.16%600.62M | 27.85%181.15M | 33.24%237.25M | 77.80%141.69M | 46.53%178.06M |
Financing cost | 62.50%-159K | ---- | ---424K | ---- | ---- | ---- | ---- | ---- | ---- | 29.29%-350K |
Share of profits of associates | -180.32%-3.02M | -161.63%-3.53M | -479.03%-1.08M | -220.67%-1.35M | ---186K | ---421K | ---- | ---- | ---- | ---- |
Share of profit from joint venture company | 68.37%-180K | 21.69%-780K | -245.52%-569K | 27.09%-996K | --391K | -2,176.67%-1.37M | ---- | ---60K | ---79K | ---- |
Earning before tax | -20.64%366.58M | 16.09%883.04M | 81.63%461.92M | 27.02%760.63M | 40.40%254.32M | 152.47%598.84M | 27.92%181.15M | 33.47%237.19M | 77.80%141.61M | 46.85%177.71M |
Tax | 1.59%-56.74M | -95.49%-157.12M | -231.01%-57.66M | 18.40%-80.37M | 50.80%-17.42M | -507.23%-98.49M | -262.55%-35.4M | 5.66%-16.22M | -4.08%-9.77M | -40.80%-17.19M |
After-tax profit from continuing operations | -23.36%309.84M | 6.71%725.92M | 70.64%404.26M | 35.96%680.26M | 62.55%236.91M | 126.43%500.34M | 10.54%145.75M | 37.66%220.97M | 87.65%131.85M | 47.52%160.52M |
Earning after tax | -23.36%309.84M | 6.71%725.92M | 70.64%404.26M | 35.96%680.26M | 62.55%236.91M | 126.43%500.34M | 10.54%145.75M | 37.66%220.97M | 87.65%131.85M | 47.52%160.52M |
Minority profit | ---- | 107.02%37K | -456.19%-584K | ---527K | ---105K | ---- | ---- | ---- | ---- | ---- |
Profit attributable to shareholders | -23.47%309.84M | 6.62%725.88M | 70.81%404.85M | 36.06%680.78M | 62.62%237.01M | 126.43%500.34M | 10.54%145.75M | 37.66%220.97M | 87.65%131.85M | 47.52%160.52M |
Basic earnings per share | -24.17%0.3072 | 5.82%0.7238 | 70.21%0.4051 | 38.35%0.684 | 70.00%0.238 | 127.73%0.4944 | 7.69%0.14 | 30.08%0.2171 | 66.67%0.13 | 25.77%0.1669 |
Diluted earnings per share | -23.99%0.3007 | 4.52%0.7118 | 66.71%0.3956 | 37.74%0.681 | 69.50%0.2373 | 127.73%0.4944 | 7.69%0.14 | 30.08%0.2171 | 66.67%0.13 | 25.77%0.1669 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.